Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4

Michael W Weiner; Dallas P Veitch; Melanie J Miller; Paul S Aisen; Bruce Albala; Laurel A Beckett; Robert C Green; Danielle Harvey; Clifford R Jack Jr; William Jagust; Susan M Landau; John C Morris; Rachel Nosheny; Ozioma C Okonkwo; Richard J Perrin; Ronald C Petersen; Monica Rivera-Mindt; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; Duygu Tosun; John Q Trojanowski; Alzheimer's Disease Neuroimaging Initiative

doi:10.1002/alz.12797

Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4

Alzheimers Dement. 2023 Jan;19(1):307-317. doi: 10.1002/alz.12797. Epub 2022 Oct 9.

Authors

Michael W Weiner^{1

2

3

4

5}, Dallas P Veitch^{1

6}, Melanie J Miller^{1

6}, Paul S Aisen⁷, Bruce Albala⁸, Laurel A Beckett⁹, Robert C Green¹⁰, Danielle Harvey⁹, Clifford R Jack Jr¹¹, William Jagust¹², Susan M Landau¹², John C Morris^{13

14

15}, Rachel Nosheny^{1

4}, Ozioma C Okonkwo¹⁶, Richard J Perrin^{13

14

15}, Ronald C Petersen¹⁷, Monica Rivera-Mindt^{18

19}, Andrew J Saykin^{20

21}, Leslie M Shaw²², Arthur W Toga²³, Duygu Tosun^{1

2}, John Q Trojanowski²²; Alzheimer's Disease Neuroimaging Initiative

Affiliations

¹ Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, California, USA.
² Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA.
³ Department of Medicine, University of California, San Francisco, California, USA.
⁴ Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, California, USA.
⁵ Department of Neurology, University of California, San Francisco, California, USA.
⁶ Northern California Institute for Research and Education (NCIRE), Department of Veterans Affairs Medical Center, San Francisco, California, USA.
⁷ Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
⁸ Department of Neurology, University of California Irvine School of Medicine, Irvine, California, USA.
⁹ Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, California, USA.
¹⁰ Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Broad Institute Ariadne Labs and Harvard Medical School, Boston, Massachusetts, USA.
¹¹ Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
¹² Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, California, USA.
¹³ Knight Alzheimer's Disease Research Center, Washington University School of Medicine, Saint Louis, Missouri, USA.
¹⁴ Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA.
¹⁵ Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA.
¹⁶ Wisconsin Alzheimer's Disease Research Center and Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
¹⁷ Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
¹⁸ Department of Psychology, Latin American and Latino Studies Institute, & African and African American Studies, Fordham University, New York, New York, USA.
¹⁹ Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
²⁰ Department of Radiology and Imaging Sciences and the Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, IN, USA.
²¹ Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
²² Department of Pathology and Laboratory Medicine and the PENN Alzheimer's Disease Research Center, Center for Neurodegenerative Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
²³ Laboratory of Neuro Imaging, Institute of Neuroimaging and Informatics, Keck School of Medicine of University of Southern California, Los Angeles, California, USA.

Abstract

Introduction: The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for Alzheimer's disease (AD) clinical trials. To improve generalizability, ADNI4 aims to enroll 50-60% of its new participants from underrepresented populations (URPs) using new biofluid and digital technologies. ADNI4 has received funding from the National Institute on Aging beginning September 2022.

Methods: ADNI4 will recruit URPs using community-engaged approaches. An online portal will screen 20,000 participants, 4000 of whom (50-60% URPs) will be tested for plasma biomarkers and APOE. From this, 500 new participants will undergo in-clinic assessment joining 500 ADNI3 rollover participants. Remaining participants (∼3500) will undergo longitudinal plasma and digital cognitive testing. ADNI4 will add MRI sequences and new PET tracers. Project 1 will optimize biomarkers in AD clinical trials.

Results and discussion: ADNI4 will improve generalizability of results, use remote digital and blood screening, and continue providing longitudinal clinical, biomarker, and autopsy data to investigators.

Keywords: Alzheimer's disease; amyloid; cerebrovascular disease; digital biomarkers; generalizability; mild cognitive impairment; plasma biomarkers; tau; underrepresented populations.

Publication types

Review
Research Support, N.I.H., Extramural

MeSH terms

Alzheimer Disease* / diagnostic imaging
Amyloid beta-Peptides
Biomarkers
Cognitive Dysfunction* / diagnostic imaging
Community Participation
Humans
Neuroimaging / methods
Stakeholder Participation

Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community-engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

Supplementary concepts

Grants and funding